Peptide Association

Insights

NewsBlog
Start free intake

DisclosurePeptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.

All peptides

Oncology · FDA Approved

Triptorelin (Trelstar)

FDA-approved

How to ask your doctor
Written by Peptide Association Editorial TeamLast reviewed Editorial policy

01 · Overview

Triptorelin is a synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH) that acts as a long-acting agonist. After an initial stimulatory phase, continued exposure downregulates pituitary GnRH receptors, suppressing luteinizing hormone and follicle-stimulating hormone and lowering sex steroid production.

In the United States the depot formulation Trelstar is approved for advanced prostate cancer and Triptodur for central precocious puberty in children; it is also used for conditions such as endometriosis in other countries. The peptide carries amino acid substitutions that increase receptor affinity and metabolic stability.

02 · Research summary & key findings

Triptorelin (Trelstar) was first FDA approved in June 2000 for palliative treatment of advanced prostate cancer, with later approvals for longer-acting depots and, in 2017, Triptodur for central precocious puberty. In a randomized comparison with leuprolide in 284 men with advanced prostate cancer, castrate testosterone levels were reached slightly more slowly with triptorelin at day 29 but maintenance of castration over 9 months was equivalent between the drugs (PMID 12887472). In children with central precocious puberty, depot triptorelin has long-standing use with suppression of the pituitary-gonadal axis and no reported long-term adverse effects on reproductive function, though adult-height outcomes vary across studies (PMID 29957076).

03 · Regulatory status

Triptorelin (Trelstar) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Triptorelin (Trelstar) is an FDA-approved medicine prescribed for the conditions on its label. It is not part of our intake, so we do not propose protocols for it. If you think it may be relevant to you, talk to your own doctor. How to ask your doctor.

04 · Administration routes

  • Intramuscular injection

References

  1. [1]Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer BJU Int, 2003. PMID 12887472
  2. [2]Triptorelin depot for the treatment of children 2 years and older with central precocious puberty Expert Rev Clin Pharmacol, 2018. PMID 29957076

Primary literature

Related peptides in Oncology

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.